S6 Ep11: ‘Stand Up For Yourself’: Facing Thyroid Cancer With Urgency, Positivity
Kate Rice is proof of the power of persistence and positivity while navigating a cancer journey. Rice, an award-winning journalist, received a diagnosis of stage 4 anaplastic thyroid cancer in Octobe...
10 Jan 202411min
S6 Ep10: FDA Stops Lung Cancer Trial, CAR-T Cell Therapy Is Cost Effective, Novel Drug Slows Fibrosis
The year 2024 is now underway. After a busy 2023, we’re now looking back at some of the oncology headlines from the new year. Notably, we have a clinical trial hold for a lung cancer drug, a trial t...
8 Jan 20247min
S6 Ep9: Top Cancer Headlines from 2023: From Jimmy Buffett’s Death to the Chemo Shortage
The year 2023 has come and gone, and we figured that now is the perfect time to look back on some of the top cancer-related stories from the year. Vitamin D May Impact Colorectal Cancer Outcomes...
2 Jan 20247min
S6 Ep8: FDA Approves 3 Treatments, Cancer Vaccine Shows Promise
The FDA is certainly staying busy as 2023 comes to a close, approving three treatments for patients with cancer last week alone. Additionally, exciting study findings were released regarding a cancer...
20 Des 20238min
S6 Ep7: Conference Highlights from the 2023 ASH Annual Meeting
This past weekend, the CURE® staff was busy covering the American Society of Hematology (ASH) Annual Meeting. ASH is the largest blood cancer conference in the country, and thousands of abstracts wer...
13 Des 20236min
S6 Ep6: Conference Highlights from SABCS
The last week was a busy one for us here at CURE® and across the oncology space in general. There were two major meetings we covered: the San Antonio Breast Cancer Symposium and the American Society o...
11 Des 20237min
S6 Ep5: Top Headlines on CAR-T Cell Therapy
Blood cancer treatments — and one treatment type, in particular — were the point of much discussion last week. The FDA said that it is investigating instances of secondary malignancies in patients wit...
4 Des 20234min
S5 Ep35: Fertility Research ‘Long Overdue’ for Patients With Cervical Cancer
For patients with cervical cancer who are negative for high-risk human papillomavirus (HPV) with normal or low-grade cytology, a prolonged follow-up interval of six months could be offered six to 24 m...
30 Nov 20238min
